Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 1:40 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1681–1704 of 3,925 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HTN Clear all

Conditions: Pulmonary Hypertension Associated With HFpEF
Interventions: TNX-103; Drug
Lead sponsor: Tenax Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 10
States / cities: Chicago, Illinois • Boston, Massachusetts • Minneapolis, Minnesota + 7 more

Conditions: ESRD, Extracellular Fluid Alteration, Hypertension
Interventions: Intradialytic Blood Pressure Slope Based Ultrafiltration; Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Hypertension
Interventions: Loop diuretics, thiazides, dihydropyridines, Telmisartan; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 55 Years and older
Enrollment: 40,048 participants
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Preeclampsia, Maternal, Hypertension, Pregnancy
Interventions: Sphygmomanometer; Device
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Orange, California

Conditions: Hypertension, Vascular Diseases, Cardiovascular Diseases
Interventions: Paradise Renal Denervation System, Renal Angiogram; Device · Procedure
Lead sponsor: ReCor Medical, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2029
U.S. locations: 28
States / cities: Birmingham, Alabama • Los Angeles, California • Bridgeport, Connecticut + 24 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Spironolactone, Placebo; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2031
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hypertension in Pregnancy
Interventions: Home Blood Pressure Telemonitoring; Device
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: Cardiovascular Diseases, Hypertension
Interventions: Normotensive, Hypertensives; Other · Drug
Lead sponsor: University of Delaware; Other
Eligibility: 50 Years to 70 Years · Female only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Newark, Delaware

Conditions: Glaucoma, Ocular Hypertension
Interventions: Bimatoprost 0.01% Ophthalmic Solution, Bimatoprost 0.03% Ophthalmic Solution, Bimatoprost Vehicle Ophthalmic Solution; Drug
Lead sponsor: Allergan; Industry
Eligibility: 20 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Healthy
Interventions: Radio-labeled rodatristat ethyl 600 mg; Drug
Lead sponsor: Altavant Sciences GmbH; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Portal Hypertension
Interventions: Chart Review; Other
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Optic Neuropathy, Glaucoma
Interventions: Hyperbaric Oxygen, Sham Hyperbaric Oxygen; Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Heart Failure, Cardiomyopathies, Pulmonary Hypertension, Myocarditis; Acute or Subacute, Myocarditis Due to Drug, Myocarditis Viral, Pericardial Diseases, Valvular Heart Diseases, Hypertension, Sepsis, Acute Kidney Injury, Pulmonary Edema - Acute, Pulmonary Edema With Heart Failure, Pulmonary Edemas, Acute Respiratory Distress Syndrome, Pulmonary Embolism Acute, Pulmonary Embolism (Diagnosis), Pulmonary Embolism Acute Massive, Pulmonary Embolism Subacute Massive, Venous Thrombosis Pulmonary, Venous Thrombosis (Disorder), Venous Thrombosis, Deep, Peripheral Arterial Disease, Peripheral Arterial Disease (PAD), Aortic Diseases, Muskuloskeletal Diseases, Brain Aging, Brain Aneurysm, Brain Aging Related Conditions, Ultrasound, Ultrasound Exams, Ultrasound Guidance
Interventions: OMNIPHYS Multimodal Ultrasound Imaging System; Device
Lead sponsor: Truway Health, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 25,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2046
U.S. locations: 1
States / cities: New York, New York

Conditions: Coarctation of Aorta, High Blood Pressure
Interventions: Losartan, Amlodipine, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Cardiovascular Disease
Interventions: ALT-711 (alagebrium chloride); Drug
Lead sponsor: Synvista Therapeutics, Inc; Industry
Eligibility: 50 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Treated Hypertension
Interventions: Lipoic Acid plus Omega-3 Fatty Acids, Placebo; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 55 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 2
States / cities: Portland, Oregon

Conditions: Hypertension, High Blood Pressure, Diabetes, Chronic Kidney Diseases
Interventions: LINKED-HEARTS Program; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 425 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland • Denton, Maryland

Conditions: Breast Carcinoma
Interventions: Laboratory Biomarker Analysis; Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 354 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2100
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Open Angle Glaucoma, Ocular Hypertension, Glaucoma, Open Angle, Pseudo-exfoliative, Pigment Dispersion Syndrome, Glaucoma
Interventions: Selective Laser Trabeculoplasty, Neodymium:Yttrium Aluminum Garnet (YAG) laser; Procedure · Device
Lead sponsor: Temple University; Other
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 2
States / cities: Wilmington, Delaware • Thorndale, Pennsylvania

Conditions: Glaucoma
Interventions: Perimetric test; Diagnostic Test
Lead sponsor: Envision Health Technologies, Inc.; Industry
Eligibility: 25 Years to 70 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Heart Failure With Preserved Ejection Fraction, Pulmonary Disease, Left Ventricular Hypertrophy/Hypertension
Interventions: Dobutamine, Amlodipine; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Pre-hypertension
Interventions: Tension Tamer (TT), Lifestyle education program (SPCTL); Behavioral
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 90 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Hypertension
Interventions: Telmisartan, Hydrochlorothiazide; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 894 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 18
States / cities: Athens, Alabama • Mobile, Alabama • Lomita, California + 14 more

Conditions: Essential Hypertension
Interventions: Not listed
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 20 Years to 99 Years
Enrollment: 1,405 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: East Hanover, New Jersey

Search by objective public record fields.

Long-Term Open-Label Extension Study of Oral Levosimendan

Using Intradialytic Blood Pressure Slopes to Guide Ultrafiltration

Replication of the TRANSCEND Antihypertensive Trial in Healthcare Claims Data

A Comparison of BNP Levels Using the Nexfin Device in Healthy Pregnant and Preeclamptic Women

The RADIANCE II Pivotal Study: A Study of the ReCor Medical Paradise System in Stage II Hypertension

Spironolactone for Pulmonary Arterial Hypertension

STAMPP-HTN in a High-risk Rural Population of Women

Vascular Dysfunction in Hypertensive Postmenopausal Women

Safety and Efficacy Study of Bimatoprost in Ethnically Japanese Patients With Open-Angle Glaucoma or Ocular Hypertension

Pharmacokinetics and Excretion of Oral [14C]-Rodatristat Ethyl

Assessing Outcome After H-graft Shunt Placement

Hyperbaric Oxygen Therapy for Optic Neuropathies

Multimodal Physiologic State Intelligence Study

A Study of Angiotensin-II Receptor Blocker on Cardiovascular Remodeling (VALUE Trial)

The STRETCH Study: Distensibility on Endothelial-Dependent Vasoreactivity in Subjects With Systolic Hypertension

Pilot Study: Lipoic Acid and Omega-3 Fatty Acids for Alzheimer's Prevention

A Cardiometabolic Health Program Linked With Clinical-Community Support and Mobile Health Telemonitoring to Reduce Health Disparities

Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Hypertension Receiving Bevacizumab for Breast Cancer

180 Degree vs. 360 Degree Selective Laser Trabeculoplasty as Initial Therapy for Glaucoma

Perimetric Testing With Virtual Reality

Reduced Contractile Reserve: a Therapeutic Target in Heart Failure With Preserved Ejection Fraction(HFpEF)

Tension Tamer Randomized Control Trial

Telmisartan 80mg Plus Hydrochlorothiazide 25mg First Line in Moderate or Severe Hypertension

Effectiveness of Entresto (Sacubitril/Valsartan) in Japanese Patients With Hypertension